Nivolumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Nivolumab and local guidelines before prescribing.
Mechanism
PD-1 inhibitor restoring T-cell antitumour activity.
Uses
Melanoma, non-small-cell lung cancer, renal cell carcinoma, Hodgkin lymphoma and other cancers.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Immune-related colitis, pneumonitis, hepatitis, thyroiditis, hypophysitis, rash, fatigue.
Interactions
Immunosuppressants and steroids reduce effect.
Contraindications and cautions
Active autoimmune disease (caution), organ transplant
Monitoring
TFT, LFT, cortisol, glucose, U&E before each cycle
Pregnancy and breastfeeding
Avoid; contraception during and for 5 months after
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive; steroids for immune toxicity
Special advice
Early recognition of immune-related adverse events; steroids for moderate to severe toxicity; carry alert card.
More from the textbook: uses, cautions and other points
- An immune-related adverse event of PD-1, PD-L1 and CTLA-4 inhibitors (e.g. pembrolizumab, nivolumab, ipilimumab). Uncommon (about 1%) but with mortality of up to a quarter to a half in fulminant cases.
Cardiology: Cardiomyopathies - A 62-year-old man on nivolumab and ipilimumab develops ptosis, proximal weakness and a troponin of 900 ng/L four weeks after starting. Answer: Checkpoint-inhibitor myocarditis with myositis/myasthenia overlap - stop immunotherapy, IV methylprednisolone, ECG monitoring for heart block, involve oncology, neurology and cardiology.
Cardiology: Cardiomyopathies - Mechanism: Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab) release the brakes on the immune system. As well as attacking the cancer, they can cause immune-related adverse events in almost any organ - at any time, even months after stopping.
Respiratory: Lung Cancer - Nivolumab + ipilimumab | First-line immunotherapy for mesothelioma (NICE TA818).
Respiratory: Lung Cancer - Immune checkpoint inhibitors (pembrolizumab, nivolumab) | Immune pneumonitis - urgent assessment; steroids
Respiratory: Anatomy, Physiology and Pharmacology - Immune checkpoint inhibitors (pembrolizumab, nivolumab) - immune-related pneumonitis.
Respiratory: Interstitial Lung Disease - Neoadjuvant chemo-immunotherapy (e.g. nivolumab with chemotherapy before surgery).
Respiratory: Lung Cancer - Immunotherapy (nivolumab plus ipilimumab, NICE TA818) or chemotherapy (platinum plus pemetrexed).
Respiratory: Lung Cancer
Where it is discussed in the book
- Cardiology: Cardiomyopathies (2 mentions)
- Respiratory: Anatomy, Physiology and Pharmacology (1 mention)
- Respiratory: Interstitial Lung Disease (1 mention)
- Respiratory: Lung Cancer (6 mentions)
- Endocrine: Anatomy Physiology and Pharmacology (1 mention)
- Gastroenterology: Oesophagus and Stomach (2 mentions)
- Gastroenterology: Inflammatory Bowel Disease (2 mentions)
- Haematology: Myeloma and Lymphoma (1 mention)
- Oncology: Principles (6 mentions)
- Oncology: Urology and Genital cancers (3 mentions)
- Oncology: Skin Cancer (2 mentions)
- Dermatology: Skin lesions and skin cancer (3 mentions)
- Rheumatology: Emergencies, pregnancy and other systemic diseases (2 mentions)
- ENT: Neck lumps and cancer (3 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (6 mentions)
- Integrated cardiology chapter (2 mentions)
- Integrated respiratory chapter (7 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)